Qiming Venture Partners and Portfolio Companies Win Multiple Awards at 2029 Healthcare Investment Excellence Awards
The Healthcare Investment Excellence Awards have served as an important barometer for assessing corporate market value and institutional brand influence in the healthcare investment industry. Since their inaugural release in 2017, the awards have recognized investment institutions, investors, and healthcare companies with outstanding performance and distinguished contributions each year.
Recently, HaoYue Capital officially released the 2025 9th Healthcare Investment Excellence Awards. As an important barometer for evaluating corporate market value and institutional brand influence in the healthcare investment industry, the Healthcare Investment Excellence Awards have been presented annually since their debut in 2017 to investment institutions, investors, and healthcare companies with outstanding performance and contributions.
This year's awards include categories for investment institutions and enterprises. Qiming Venture Partners and seven of its portfolio companies made the list.
Qiming Venture Partners was named Healthcare Investment Fund of the Year, Best Innovative Pharmaceutical Investment Institution of the Year, Best Innovative Medical Device Investment Institution of the Year, Best IVD and Life Sciences Investment Institution of the Year, Best Health Services and Smart Healthcare Investment Institution of the Year, and Best Biotechnology Investment Institution of the Year. William Hu, Managing Partner at Qiming Venture Partners, was named Healthcare Investor of the Year, and Jing Liu, Executive Director at Qiming Venture Partners, was named Young Healthcare Investor of the Year.
Qiming Venture Partners
Named
Healthcare Investment Fund of the Year
Best Innovative Pharmaceutical Investment Institution of the Year
Best Innovative Medical Device Investment Institution of the Year
Best IVD and Life Sciences Investment Institution of the Year
Best Health Services and Smart Healthcare Investment Institution of the Year
Best Biotechnology Investment Institution of the Year
William Hu, Managing Partner at Qiming Venture Partners
Named
Healthcare Investor of the Year
Jing Liu, Executive Director at Qiming Venture Partners
Named
Young Healthcare Investor of the Year
Qiming Venture Partners portfolio companies TianChen Bio, DK MedTech, Jieti Medical, JingYu Medical, RuiNing Bio, Wushuang Medical, and LaNova Medicines were selected for the awards.
TianChen Bio
Named
Best Innovative Pharmaceutical Enterprise of the Year
DK MedTech, Jieti Medical, JingYu Medical
RuiNing Bio, Wushuang Medical
Named
Best Innovative Medical Device Enterprise of the Year
LaNova Medicines
Selected for
Healthcare Product BD Cooperation List of the Year
- 9th Healthcare Investment Excellence Awards
The awards comprehensively evaluate healthcare investment funds based on investment activity, deal volume, transaction value, and investment returns, among other metrics, to identify outstanding investment institutions of the year. Awards are also presented to excellent healthcare enterprises across sectors including innovative pharmaceuticals, innovative medical devices, IVD and life sciences, health services and smart healthcare, and biotechnology.
Over the past year, the industry witnessed the global surge of GLP-1 drugs, continued momentum in ADCs, AI-driven revolutions in diagnosis and treatment, and the boundless possibilities brought by brain-computer interfaces and gene editing. Behind the international breakthroughs of innovative drugmakers, intelligent upgrades in medical devices, and ecological integration of digital health lies "China's intelligent manufacturing" engaging with global markets with greater sobriety and depth. Whether through the thousand-plus financing and investment transactions each year, or record-breaking license-out and license-in deals; whether through technological innovation or institutional innovation, all have helped Chinese healthcare enterprises cultivate their home turf with precision, seek synergistic leaps through mergers and acquisitions, and blaze new trails on the path to globalization.
Source | HaoYue Capital
Past Highlights
Qiming Honors | Qiming Venture Partners and Portfolio Companies Win Multiple Awards at 2024 8th Healthcare Investment Excellence Awards Qiming Honors | Qiming Venture Partners and Executive Director Shuo Mao Named to 2025 H1 Pioneer List and Other Rankings Qiming Honors | Qiming Venture Partners and Multiple Portfolio Companies Selected for 2024-2025 China Technology Industry Investment Rankings
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management of $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Genrix Bio (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.